NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 287 filers reported holding NOVOCURE LTD in Q3 2020. The put-call ratio across all filers is 0.96 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $466,283 | +44.8% | 28,872 | +272.1% | 0.00% | 0.0% |
| Q2 2023 | $322,041 | -62.5% | 7,760 | -45.7% | 0.00% | -50.0% |
| Q1 2023 | $858,979 | +72756.6% | 14,283 | -11.1% | 0.00% | -33.3% |
| Q4 2022 | $1,179 | -99.9% | 16,061 | +1.5% | 0.00% | -25.0% |
| Q3 2022 | $1,203,000 | +10.0% | 15,831 | +0.5% | 0.00% | +33.3% |
| Q2 2022 | $1,094,000 | -4.0% | 15,746 | +82.7% | 0.00% | 0.0% |
| Q1 2021 | $1,139,000 | -4.6% | 8,619 | +24.9% | 0.00% | -25.0% |
| Q4 2020 | $1,194,000 | +37.7% | 6,899 | -11.4% | 0.00% | +33.3% |
| Q3 2020 | $867,000 | +238.7% | 7,787 | +80.4% | 0.00% | +200.0% |
| Q2 2020 | $256,000 | -2.3% | 4,316 | +10.9% | 0.00% | 0.0% |
| Q1 2020 | $262,000 | +21.9% | 3,891 | +52.8% | 0.00% | 0.0% |
| Q4 2019 | $215,000 | -14.7% | 2,546 | -24.5% | 0.00% | 0.0% |
| Q3 2019 | $252,000 | – | 3,373 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $26,344,000 | 8.01% |
| HARTLINE INVESTMENT CORP/ | 318,109 | $23,884,000 | 3.27% |
| Deep Track Capital, LP | 550,000 | $41,294,000 | 2.92% |
| MORGAN JESS S & CO INC | 43,975 | $3,302,000 | 2.03% |
| Taylor Frigon Capital Management LLC | 46,376 | $3,482,000 | 1.09% |
| Darsana Capital Partners LP | 258,937 | $19,441,000 | 0.90% |
| Private Harbour Investment Management & Counsel, LLC | 13,562 | $1,018,000 | 0.81% |
| Rhenman & Partners Asset Management AB | 120,387 | $9,610,000 | 0.64% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $751,000 | 0.50% |
| Baillie Gifford | 9,615,168 | $721,906,000 | 0.40% |